Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
MYO Catalyst Timeline
Dated clinical, regulatory and corporate events for Myomo Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Myomo Inc.
Past FDA Catalysts and PDUFA Decisions
How MYO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Myomo Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MYO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kovelman HarryOfficer (Chief Medical Officer) | Sell | -15,488 90,245 held | $1.27 | 09/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MYO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0 % (-100 %) | 628.21 K | 704.27 K |
Ownership Trends
MYO Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How MYO ranks across every disease it competes in
MYO News
Myomo Reports Third Quarter 2026 Financial and Operating Results
Myomo reported third-quarter 2026 revenue of $12.3 million, a 22% increase year-over-year. The company achieved breakeven Adjusted EBITDA and saw 54% of revenue from recurring patient sources. Myomo narrowed its full-year revenue guidance to $46-47 million, indicating positive operational progress despite a net loss of $4.2 million.
Read more →Myomo to Attend the 17th Annual Craig Hallum Alpha Select Conference
Myomo, Inc. will participate in the 17th Annual Craig Hallum Alpha Select Conference on November 17, 2026. Executives including CEO Paul Gudonis will hold one-on-one meetings with investors. The company specializes in wearable medical robotics that assist individuals with upper-limb paralysis.
Read more →Myomo to Report Third Quarter 2026 Financial Results on November 9
Myomo, Inc. will announce its financial results for Q3 2026 on November 9, 2026. The company will hold a conference call at 4:30 p.m. Eastern time to discuss the results and provide updates. Myomo specializes in wearable medical robotics to assist those with neurological disorders and upper-limb paralysis.
Read more →Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
Myomo, Inc. has appointed Mary-Katherine McClure as the new Chief Commercial Officer, effective October 12, 2026. She succeeds Micah Mitchell, who is leaving the company after a leadership transition period. McClure brings over 20 years of experience in the industry, which is expected to enhance Myomo's commercial strategies.
Read more →Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Myomo, Inc. has announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte Palace Hotel in New York. The company aims to highlight its advancements in wearable medical robotics designed for individuals with neurological disorders and upper-limb paralysis. This event is expected to enhance Myomo's visibility in the investment community.
Read more →Myomo Reports Second Quarter 2026 Financial and Operating Results
Myomo, Inc. reported its financial results for Q2 2026, highlighting a revenue of $11.7 million, which surpassed expectations. The company attributes this success to an evolved go-to-market strategy aimed at enhancing its offerings for individuals with neurological disorders and upper-limb paralysis. Overall, the results indicate a positive trajectory for Myomo.
Read more →Myomo to Report Second Quarter 2026 Financial Results on August 5
Myomo, Inc. has announced the date for its second quarter financial results, which will be reported on August 5, 2026. The company specializes in wearable medical robotics aimed at aiding those with neurological disorders and upper-limb paralysis. A conference call will follow the report to discuss the results and provide business updates.
Read more →Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
Myomo, Inc. announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026. The event will take place on June 23-24, where CEO Paul Gudonis and CFO David Henry will present and meet with investors. A live webcast of the presentation will be available, along with a replay afterward.
Read more →Myomo Announces Participation in Upcoming Investor Conferences
Myomo, Inc. has announced its participation in two upcoming investor conferences. CEO Paul Gudonis and CFO David Henry will engage in a fireside chat at the Alliance Global Partners Annual Healthcare Company Showcase on May 20. Additionally, CFO David Henry will present at Sidoti's Virtual Micro Cap Conference on May 21, which will include one-on-one investor meetings.
Read more →Myomo Appoints Joseph M. Manko to its Board of Directors
Myomo, Inc. has appointed Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026. Manko brings over 25 years of experience in investment banking, private equity, and corporate strategy, including his role as Senior Principal of Horton Capital Management LLC. His addition to the board aims to support Myomo's growth strategy and enhance shareholder value, while the company continues to develop its innovative technology for patients with neurological disorders and upper-limb paralysis.
Read more →Myomo Reports First Quarter 2026 Financial and Operating Results
Myomo, Inc. reported its financial results for Q1 2026, achieving revenue of $10.1 million, a 3% increase from the previous year. The company noted a significant shift towards recurring patient revenue sources, which now account for 49% of total revenue. Operating losses decreased, and gross margins improved, indicating positive operational trends. Myomo anticipates continued revenue growth in the upcoming quarter.
Read more →Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.
Myomo, Inc. has announced that its MyoPro powered arm brace will be available at Ottobock Care clinics across the U.S. This initiative aims to assist individuals suffering from upper extremity impairments due to conditions such as stroke and brachial plexus injury. The collaboration enhances Ottobock Care's offerings in neuro-robotic solutions for patients.
Read more →Myomo to Report First Quarter 2026 Financial Results on May 7
Myomo, Inc. will announce its financial results for the first quarter of 2026 on May 7. The company specializes in wearable medical robotics for individuals with neurological disorders. A conference call will follow the announcement, allowing management to discuss results and answer questions from participants.
Read more →Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
Myomo, Inc. has launched the Myomo Mobile App to enhance the MyoPro experience for clinicians and patients. This app aims to provide a more intuitive and connected care process, allowing clinicians to customize settings and monitor patient usage effectively. The initiative is expected to improve patient engagement and care management.
Read more →Myomo Appoints William J Febbo to its Board of Directors
Myomo, Inc. has appointed William J Febbo to its Board of Directors effective April 14, 2026. Febbo brings over 30 years of experience in healthcare and technology-driven businesses, which is expected to support Myomo's strategic initiatives for 2026 and beyond. He is recognized for his successful track record in guiding organizations through growth and transformation. This addition to Myomo's board is viewed as a crucial step towards strengthening the company's position in the wearable medical robotics market.
Read more →Myomo and Elevance Health Agree to Contract for Multi-State Network Participation
Myomo, Inc. has announced a contract with Elevance Health to participate in a multi-state network. This agreement will include Anthem-affiliated plans and is expected to roll out market-by-market through Q2 2026. The deal will increase Myomo's covered lives to over 80 million, enhancing its market presence.
Read more →Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Myomo, Inc. announced its financial results for Q4 and full year 2025, reporting a revenue of $11.4 million for the quarter and $40.9 million for the year. The company emphasized growth from recurring patient sources, which constituted 42% of its fourth quarter revenue. Myomo recorded its highest number of authorizations and orders in the fourth quarter and introduced a revenue guidance for 2026 of $43 million to $46 million. However, the company faced challenges with a 6% decline in quarterly revenue compared to the same period last year and increased operating losses.
Read more →Myomo to Report Fourth Quarter 2025 Financial Results on March 9
Myomo, Inc. will announce its financial results for Q4 and the full year of 2025 on March 9, 2026. The company, known for its wearable medical robotics, will hold a conference call at 4:30 p.m. ET to discuss the results and provide a business update. This event reflects the company's commitment to transparency.
Read more →Myomo Reports Third Quarter 2025 Financial and Operating Results
Myomo, Inc. reported its financial results for the third quarter of 2025, revealing revenue of $10.1 million, marking a 10% rise compared to the same period last year. The company noted its highest number of authorizations and orders, totaling 229, and reiterated its full-year revenue guidance of $40 to $42 million. However, Myomo faced challenges as it recorded an operating loss of $3.5 million, which is larger than the prior year's loss, alongside a decrease in gross margin due to increased costs. Despite these challenges, Myomo is optimistic about its new strategy to enhance patient referrals through its MyoConnect program.
Read more →Myomo to Report Third Quarter 2025 Financial Results on November 10
Myomo, Inc. will announce its financial results for Q3 2025 on November 10, 2025. The company specializes in wearable medical robotics aimed at aiding those with neurological disorders and upper-limb paralysis. A conference call will follow the announcement to discuss results and provide updates.
Read more →